清宣止咳颗粒联合西药治疗肺炎支原体肺炎的临床疗效及对患儿肺功能、免疫功能的影响

doi:10.3969/j.issn.1671-7171.2024.02.031

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1189 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨清宣止咳颗粒联合西药治疗肺炎支原体肺炎的临床疗效及对患儿肺功能、免疫功能的影响。【方法】选取2020年9月至2022年10月本院收治的112例肺炎支原体肺炎患儿,采用随机数字表法将其分为观察组和对照组,每组56例。对照组均予以常规西药治疗,观察组在对照组的基础上予以清宣止咳颗粒,两组均治疗2周。比较两组疗效、症状消失时间与治疗前后肺通气功能[第1秒用力呼气容积(FEV₁)、用力肺活量(FVC)、最大呼气流量(PEF)]、血清免疫球蛋白指标[免疫球蛋白M(IgM)、免疫球蛋白G(IgG)、免疫球蛋白A(IgA)]、Toll样受体4(TLR4)、髓样分化因子88(MyD88)、核转录因子-κB(NF-κB)水平,统计不良反应发生情况。【结果】观察组总有效率高于对照组,差异有统计学意义(P＜0.05)。观察组退热时间、气促消失时间、咳嗽消失时间及肺部啰音消失时间短于对照组,差异有统计学意义(P＜0.05)。治疗后,两组患者FEV₁、FVC、PEF均高于治疗前,且观察组高于对照组,差异有统计学意义(P＜0.05);两组血清IgM、IgG、IgA水平高于治疗前,观察组高于对照组,差异有统计学意义(P＜0.05);两组血清TLR4、MyD88、NF-κB表达水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P＜0.05)。两组患儿不良反应发生率比较,差异无统计学意义(P>0.05)。【结论】清宣止咳颗粒联合西药治疗肺炎支原体肺炎的临床疗效较好,可有效改善患儿肺功能与免疫功能,抑制TLR4/MyD88表达,且安全性好。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	秦俊峰
	徐国超
	安云英
	赵甜

关键词 ：肺炎,支原体/中西医结合疗法, 呼吸功能试验, 免疫学试验

Abstract：【Objective】To explore the clinical efficacy of Qingxuan Zhike Granules combined with Western medicine in the treatment of Mycoplasma pneumoniae pneumonia and its impact on lung function and immune function in children. 【Methods】A total of 112 children with Mycoplasma pneumoniae pneumonia admitted to our hospital from September 2020 to October 2022 were selected and randomly divided into an observation group and a control group using a random number table method, with 56 cases in each group. The control group was treated with conventional western medicine, while the observation group was treated with Qingxuan Zhike Granules on the basis of the control group. Both groups were treated for 2 weeks.The two groups were compared in terms of efficacy, symptom disappearance time, and pulmonary ventilation function before and after treatment [forced expiratory volume at 1 second (FEV₁), forced vital capacity (FVC), maximum expiratory flow rate L (PEF)], serum immunoglobulin indicators [immunoglobulin M (IgM), immunoglobulin G (IgG), immunoglobulin A (IgA)],Toll like receptor 4 (TLR4), myeloid differentiation factor 88 (MyD88), and nuclear transcription factor-κB (NF-κB) levels. The occurrence of adverse reactions had been counted. 【Results】The total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). The observation group had shorter fever relief time, disappearance time of shortness of breath, disappearance time of cough, and disappearance time of lung rales compared to the control group, and the differences were statistically significant (P<0.05). After treatment, the FEV₁, FVC, and PEF of the two groups of patients were higher than before treatment, and the observation group was higher than the control group, with statistical significance (P<0.05); The serum levels of IgM, IgG, and IgA in the two groups were higher than before treatment, while the observation group was higher than the control group, with statistical significance (P<0.05); The expression levels of TLR4, MyD88, and NF-κB in the serum of the two groups were lower than before treatment, and the observation group was lower than the control group, with statistical significance (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups of children (P>0.05). 【Conclusion】The combination of Qingxuan Zhike Granules and Western medicine has a good clinical efficacy in the treatment of Mycoplasma pneumoniae pneumonia, which can effectively improve the lung and immune functions of children, inhibit the expression of TLR4/MyD88, and is safe.

Key words： Pneumonia, Mycoplasma/ ZJ Respiratory Function Tests Immunologic Tests

收稿日期: 2023-05-31

中图分类号:

R725.631

引用本文:

秦俊峰, 徐国超, 安云英, 赵甜. 清宣止咳颗粒联合西药治疗肺炎支原体肺炎的临床疗效及对患儿肺功能、免疫功能的影响[J]. 医学临床研究, 2024, 41(2): 269-272.
QIN Junfeng, XU Guochao, AN Yunying, et al. Clinical Efficacy of Qingxuan Zhike Granules Combined with Western Medicine in the Treatment of Mycoplasma Pneumoniae Pneumonia and its Impact on Lung and Immune Function in Children. JOURNAL OF CLINICAL RESEARCH, 2024, 41(2): 269-272.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.02.031 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I2/269

[1] LEE H,YUN K W,LEE H J,et al.Antimicrobial therapy of macrolide-resistant Mycoplasma pneumoniae pneumonia in children[J].Expert Rev Anti Infect Ther,2018,16(1):23-34.
[2] 张淑利.桉柠蒎肠溶软胶囊联合哌拉西林舒巴坦治疗社区获得性肺炎疗效观察[J].新乡医学院学报,2019,36(8):759-763.
[3] 牛春梅.小儿热速清颗粒联合阿奇霉素治疗小儿肺炎支原体肺炎的疗效[J].中国药物与临床,2020,20(16):2767-2769.
[4] 江载芳,申昆玲,沈颖.诸福棠实用儿科学[M]. 8版.北京:人民卫生出版社,2015:1204-1205.
[5] 刘道路,郭轲,王颖.宣肺止咳方联合西药治疗对支原体肺炎患儿心肌酶指标的影响[J].四川中医,2020,38(8):86-89.
[6] 吴俊,雷后兴,傅剑芬,等.头孢他啶钠联合阿奇霉素治疗小儿肺炎支原体肺炎的临床疗效及安全性探讨[J].中国现代医生,2019,57(8):56-58.
[7] CHO Y J,HAN M S,KIM W S, et al. Correlation between chest radiographic findings and clinical features in hospitalized children with Mycoplasma pneumoniae pneumonia[J].PLoS One,2019,14(8):e0219463.
[8] 张磊,韩丽.连花清瘟颗粒联合哌拉西林舒巴坦治疗肺炎的临床观察[J].现代药物与临床,2018,33(8):1960-1963.
[9] 李巧特,蔡伟泽,杨燕青,等.小儿宣肺止咳颗粒治疗小儿支气管肺炎[J].海峡药学,2019,31(4):250-251.
[10] 宗阳,姚卫峰,单进军,等.基于网络药理学和分子对接法探寻清宣止咳颗粒治疗儿童新型冠状病毒肺炎活性化合物[J].世界中医药,2020,15(4):477-483.
[11] YANG M,MENG F,GAO M, et al. Cytokine signatures associate with disease severity in children with Mycoplasma pneumoniae pneumonia[J].Sci Rep,2019,9(1):17853.
[12] 韦瑞含,罗晶丹,王毅.小儿肺炎支原体肺炎发病机制与血清免疫球蛋白A、免疫球蛋白M、免疫球蛋白G水平相关性研究[J].临床军医杂志,2018,46(4):77-78.
[13] 张静,张冠,李倩,等.血清补体与IgA、IgM、IgG联合检测在肺炎支原体肺炎诊断中的价值研究[J].河北医药,2019,41(19):2990-2992.
[14] 廖震.丙种球蛋白联合阿奇霉素治疗小儿肺炎支原体肺炎的疗效及对C反应蛋白、免疫球蛋白水平的影响[J].中国妇幼保健,2018,33(6):1324-1327.
[15] 郭冰冰,路明,武怡.重症肺炎支原体肺炎患儿血清Toll样受体4/髓样分化因子88及D-二聚体水平检测的意义[J].中华实用儿科临床杂志,2017,32(22):1709-1712.